This Ratio Explains Why I’d Buy AstraZeneca plc Today

AstraZeneca plc (LON:AZN) offers a 5.4% yield, but there’s a more compelling reason to buy this firm’s shares, as Roland Head explains.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AstraZeneca (LSE: AZN) (NYSE: AZN.US) has been much abused for its failure to invest in new products during the reign of ex-CEO David Brennan, and is undoubtedly suffering the consequences now, with both sales and earnings expected to fall for the next couple of years.

However, I reckon that investors might be overlooking one key factor, which suggests that AstraZeneca is already outrageously cheap compared to GlaxoSmithKline — and that now could be a cracking time to buy into Astra.

An important ratio

The faithful price-to-earnings ratio is a great tool for comparing the price of two similar companies, but sometimes it doesn’t tell the whole story. One problem in particular is with debt — the P/E ratio only looks at market capitalisation, and does not reflect a company’s debt levels.

Passive income stocks: our picks

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

For this reason, anyone considering buying a company usually shuns the P/E ratio and instead calculates the enterprise value to EBITDA ratio. Enterprise value is the true cost of a company — the sum of its market capitalisation and net debt — while EBITDA is earnings before interest, tax, depreciation and amortisation, which provides a measure of a firm’s raw profits.

By now you’ve probably guessed what’s coming — on an EV/EBITDA basis, AstraZeneca is exactly half the price of GlaxoSmithKline.

Why is AstraZeneca so cheap?

AstraZeneca currently boasts a modest EV/EBITDA ratio of 5.6, while Glaxo trades on a heady EV/EBITDA of 11.2.

Some of this pricing discrepancy can be accounted for by the fact that, unlike Astra, Glaxo has largely recovered from the patent cliff. But there must be another explanation, as well.

I think that the real reason for this massive difference in valuation is debt. Borrowing costs for big companies are low at the moment, and markets seem to be ignoring the risk that borrowing might become more expensive in the future, or that profits might fall, making it harder for companies to service their debts and pay dividends.

Glaxo has net debt of £15.7bn, giving it net gearing of 245%. AstraZeneca, in contrast, had net cash until the end of 2011, and currently has net gearing of just 5.6%.

This difference isn’t reflected in the valuations of the two companies, but I think it will be eventually, making AstraZeneca a very affordable and safe buy today, despite its short-term earnings weakness.

This AI stock is becoming a digital juggernaut in a £ 12.5 billion market!

🤖 Curious about the next big player in AI? 🤖

Our leading industry analysts have uncovered a trailblazing content platform that's revolutionising the industry with its unparalleled generative AI technology, setting new standards in creativity and efficiency.

Care for a sneak peek?

Trusted by global giants like Amazon, Disney, and Netflix, this innovative company is not just transforming digital media with AI-generated 3D content but is also capturing a significant share of a £12.7 billion market!

With a remarkable 62% gross margin, indicating exceptional profitability and operational efficiency, this company's growth trajectory positions it as a must-watch for savvy investors.

Best of all, we're offering exclusive access to the name of this game-changing stock, absolutely free!

Discover your free AI stock pick

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Roland owns shares in GlaxoSmithKline but does not own shares in AstraZeneca. The Motley Fool has recommended GlaxoSmithKline.

Our best passive income stock ideas

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

More on Investing Articles

Investing Articles

Up 20% in a month, should investors consider buying Marks & Spencer shares?

Shares in retailer Marks and Spencer have surged ahead over the last month, despite a cyberattack. Roland Head takes a…

Read more »

Charticle

Here are the latest growth and share price targets for Nvidia stock

Ben McPoland checks out the latest forecasts for Nvidia stock to assess whether it might be worth considering for a…

Read more »

Growth Shares

Yikes! This could be the most undervalued growth stock in the FTSE 100

Jon Smith flags up a growth stock with a low price-to-earnings ratio and a share price back at 2020 levels…

Read more »

Abstract bull climbing indicators on stock chart
Investing Articles

3 beaten-down FTSE 250 shares to consider buying before the next bull market

Paul Summers thinks brave investors should ponder buying some of the FTSE 250s poor performers before they recover strongly.

Read more »

Investing Articles

Gold prices soar while the Fresnillo share price slumps. What gives?

With a gold bull market in full swing, this Fool argues that the falling Fresnillo share price may not remain…

Read more »

Investing Articles

2 FTSE 100 shares I’m avoiding like the plague right now

While the FTSE remains packed with opportunity, many of the index's blue-chip shares could be at risk as trade tariffs…

Read more »

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

Here’s how an investor could aim for a million buying under 10 shares

Christopher Ruane explains why doing less, not more, of the right things could be the key to success as an…

Read more »

Investing Articles

Could this new risk cause a stock market crash?

Tariffs and a potential recession are two major stock market risks right now. But there’s another risk that concerns Edward…

Read more »